Articles tagged "Heart transplant patients"

2022 American Transplant Congress
Impact of Donor and Recipient Characteristics on Early Post-Transplant Donor-Derived Cell-Free DNA (dd-cfDNA) Scores
A. Alam¹, J. Zeng², J. Teuteberg³, S. Hall¹
¹Baylor University Medical Center, Dallas, TX, ²CareDx, Brisbane, CA, ³Stanford University, Stanford, CA
*Purpose: Dd-cfDNA (AlloSure, CareDx; Brisbane, CA) has been demonstrated to detect allograft injury after heart transplantation in a large and diverse patient cohort in the…
2022 American Transplant Congress
Transition Program for Young Adults with Solid Organ Transplant a Single Center Protocol
H. Y. Lee
Program for Pediatric Cardiomyopathy, Heart Failure, and Cardiac Transplantation, Columbia University Irving Medical Center, New York, NY
*Purpose: The transition process for young adult solid organ transplant patient is an important clinical milestone in a transplant patient's life. Evidenced based research demonstrates…
2022 American Transplant Congress
Fontan versus Non-Fontan Combined Heart-Liver Transplantation: Proceed but Cautiously
I. A. Ziogas, W. K. Wu, M. Izzy, A. Shingina, C. Benson, K. L. Mishra, A. S. Shah, N. L. Do, W. G. McMaster, J. N. Menachem, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Combined heart-liver transplantation (CHLT) is increasing, corresponding with a growing prevalence of Fontan-associated end-organ damage. We aimed to describe our contemporary institutional experience with…
2022 American Transplant Congress
A Sign of Things to Come? Clinical Markers After Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients
D. T. Kim¹, E. J. Henricksen², B. M. Zhang³, J. J. Teuteberg¹, Y. Moayedi⁴, H. I. Luikart¹, J. Han⁵, B. Wayda¹, K. Khush¹
¹Cardiology, Stanford University, Stanford, CA, ²Transplant, Stanford Health Care, Stanford, CA, ³Pathology, Stanford University, Stanford, CA, ⁴Cardiology, University Health Network, Toronto, ON, Canada, ⁵Cardiology, University of Chicago, Chicago, IL
*Purpose: Endomyocardial biopsy (EMBx) has historically been the standard of care for surveillance post heart transplant (HTx), but is limited by sample area and interpretation.…
2021 American Transplant Congress
Acute Dialysis, Mortality and Renal Failure After Heart Alone Transplant by Egfr and Dialysis Requirement in the United States
M. Aljuhani¹, T. Alexy¹, S. Jackson², C. Martin¹, R. Kandaswamy³, S. Riad¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, Fairview Health Services, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: We examined the early acute dialysis, 90-day mortality and one-year ESRD among OHT recipients by eGFR and dialysis requirement before transplantation.*Methods: Utilizing the SRTR…
2021 American Transplant Congress
Cyp3a5 Extensive Metabolizer Phenotype May be Associated with an Increase in Class 2 Donor Specific Antibodies and Antibody-Mediated Rejection
S. Mirza¹, N. Wilson², J. Van Zyl², P. Nguyen², T. Sam², S. Hall², M. Askar², R. Patel²
¹Texas Tech Univeristy Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX, ²Baylor University Medical Center at Dallas, Dallas, TX
*Purpose: Tacrolimus (TAC) metabolism is highly dependent on CYP3A5, yet there is limited data on the effect of CYP3A5 genetic polymorphisms in heart transplant recipients…
2021 American Transplant Congress
Randomized Phase 3 Open-label Study of Maribavir vs Investigator-assigned Therapy for Refractory/resistant Cytomegalovirus Infection in Transplant Recipients: Subgroup Analyses of Efficacy by Organ
R. K. Avery¹, E. A. Blumberg², D. Florescu³, N. Kamar⁴, D. Kumar⁵, J. Wu⁶, A. Sundberg⁶
¹Johns Hopkins Hospital, Baltimore, MD, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska School of Medicine, Omaha, NE, ⁴Hôpital de Rangueil, Toulouse, France, ⁵University Health Network, Toronto, ON, Canada, ⁶Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, KY
*Purpose: Therapeutic options for refractory, with/without resistance (R/R), CMV infections are limited. We report organ type subgroup analyses from a large multi-center trial that studied…
2021 American Transplant Congress
The Co-Occurrence of Newly Developed HLA Donor Specific Antibody and Positive C3d/C4d Profiles Along with Immune Therapy Non-Compliance in Pediatric Heart Transplant Recipients is a High Risk Indicator for Patient Mortality
A. Zhang, C. Nasman, J. Allen, Y. Sun, D. Thomas, R. Rodriguez, C. Tan, G. Boyle
Cleveland Clinic Foundation Transplant Center, Cleveland, OH
*Purpose: Increasing evidence has implicated the deleterious effect of HLA donor specific antibody (DSA) in pediatric heart transplantation (PHTx). However, there are still insufficient research…
2021 American Transplant Congress
Cardiac Outcomes in Isolated Heart and Simultaneous Kidney and Heart Transplants in the US
K. A. Agarwal¹, H. Patel¹, N. Agrawal¹, F. Cardarelli¹, N. Goyal²
¹Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ²Nephrology, Tufts Medical Center, Boston, MA
*Purpose: Kidney dysfunction is not uncommon in patients with advanced heart failure. Simultaneous kidney and heart transplants (SKHT) have gained acceptance as treatment for patients…
2021 American Transplant Congress
The Perfect Candidate? The Stanford Integrated Psychosocial Assessment for Transplant
E. J. Henricksen¹, K. Stott², S. Ilango², Y. Moayedi³, K. Waddell⁴, H. I. Luikart⁴, J. Twiggs⁴, R. Lee¹, B. M. Zhang⁵, W. Hiesinger⁶, K. K. Khush⁴, J. J. Teuteberg⁴
¹Transplant, Stanford Healthcare, Stanford, CA, ²Social Work, Stanford Healthcare, Stanford, CA, ³Cardiology, University Health Network, Toronto, ON, Canada, ⁴Cardiology, Stanford University, Stanford, CA, ⁵Pathology, Stanford University, Stanford, CA, ⁶Cardiothoracic Surgery, Stanford University, Stanford, CA
*Purpose: The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) is a tool used to objectify and enhance the pre-transplant psychosocial evaluation. We sought to assess…

« Previous Page
1
…
3
4
5
6
7
…
30
Next Page »